Fusion Antibodies

Fusion Antibodies is a contract research organization based in Belfast, United Kingdom, that specializes in the research, development, and manufacture of recombinant proteins and monoclonal antibodies, primarily targeting cancer and infectious diseases. The company provides a comprehensive range of services, including monoclonal antibody discovery and development, antibody engineering, humanization, affinity maturation, and reformatting. It also offers antibody sequencing, custom expression and purification of recombinant proteins, and cell line development services. Fusion Antibodies operates on a fee-for-service basis, allowing clients in the pharmaceutical, biotech, and diagnostic sectors to tailor project components to their specific needs. The company has established partnerships, including a collaboration with Celonic AG for developing high-yield stable cell lines, and generates a significant portion of its revenue from North America. Founded in 2001, Fusion Antibodies combines advanced technology with in-house expertise to deliver high-quality humanized monoclonal antibodies essential for advancing drug development.